MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary

MoonLake Immunotherapeutics

10/08/2026 14:32

MoonLake Immunotherapeutics MLTX.OQ reported a quarterly adjusted loss of 84 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -87 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 92 cents per share. Wall Street expected results to range from $-1.02 to -75 cents per share.
Reported revenue was zero​; analysts expected zero. 
MoonLake Immunotherapeutics's reported EPS for the quarter was a loss of 84 cents​.
The company reported a quarterly loss of $61.81 million.
MoonLake Immunotherapeutics shares had fallen by 6.2% this quarter and gained 38.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $30.00, about 39.1% above its last closing price of $18.26
This summary was machine generated from LSEG data August 10 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.92
-0.84
Beat
Mar. 31 2026 
-0.89
-0.98
Missed
Dec. 31 2025 
-0.99
-0.92
Beat
Sep. 30 2025 
-0.88
-1.10
Missed